SEHK:3933Pharmaceuticals
A Look At United Laboratories (SEHK:3933) Valuation After 2025 Earnings Guidance And Insulin Degludec Approval
Why United Laboratories’ latest guidance and insulin approval matter for investors
United Laboratories International Holdings (SEHK:3933) has issued 2025 earnings guidance pointing to lower group profit, alongside a fresh China approval for its Insulin Degludec Injection, a combination that could reshape how investors think about its earnings mix.
See our latest analysis for United Laboratories International Holdings.
The share price has eased to HK$10.48, with a 1-day share price return of...